Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation

Sponsor
University Hospital Pilsen
Study ID
NCT07570407
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • blood draw — DIAGNOSTIC_TEST
    Blood draw for diagnostic test

Study Details

The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.

Key Dates

First listed
May 6, 2026
Start date
Aug 1, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2028
Completion
Jan 31, 2029

Study Design

Enrollment
75 participants (estimated)

Arms

  • Arm: HSCT patients
    Patients who have undergone allogeneic hematopoietic cell transplantation and have been diagnosed with acute myeloid leukemia.

Primary Outcome Measure

Detection of peripheral blood iNKTs after HSCT using flow cytometry [ Time Frame: Day 30, day 60, day 90 ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies